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Summary The associations between serum concentrations of oestradiol, progesterone, testosterone and sex hormone-binding globulin
(SHBG) and risk of breast cancer in premenopausal women were investigated in a prospective study of breast cancer on the island of
Guernsey. Sixty-two women diagnosed with breast cancer an average of 8 years subsequent to blood collection were matched for day of
menstrual cycle, age and year of blood collection with 182 control subjects. Cases had a 12% higher mean oestradiol concentration over
the whole menstrual cycle (P= 0.17) with a large difference at mid-cycle (75% higher, P= 0.04). Differences between cases and control
subjects in progesterone (luteal phase), testosterone and SHBG were small and not statistically significant: luteal phase progesterone 9%
lower in cases, P = 0.64; testosterone 4% higher, P = 0.57; SHBG 8% higher, P = 0.24. The small difference in oestradiol concentration could
be aetiologically important, but larger prospective studies are needed.
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The role of endogenous sex hormones in the aetiology of breast
cancer has been debated for over 30 years. Epidemiological
studies in post-menopausal women have supported the hypothesis
that risk is associated with high levels of endogenous oestradiol
(Key and Pike, 1988; Toniolo et al 1995; Berrino et al, 1996;
Dorgan et al, 1996; Thomas et al, submitted for publication). The
investigation of premenopausal hormones and risk is more diffi-
cult because oestradiol concentrations vary widely across the
menstrual cycle and because progesterone might augment the
mitogenic action of oestradiol (Pike et al, 1993). It has also been
suggested that high concentrations of testosterone may increase
risk (Malarkey et al, 1977; Secreto et al, 1984, 1989).
The results ofearly case-control studies ofoestradiol and proges-
terone concentrations among premenopausal women are inconsistent
(Key andPike, 1988),andany differences in serumhormone concen-
trations seen between cases and control subjects could have been
caused by metabolic effects ofthe disease. Forexample, Bernstein et
al (1990) reported lowerprogesterone concentrations inbreast cancer
cases than in control subjects but this difference was reversed when
women with anovulatory cycles were excluded (this occurred in a
largerproportion ofcases than control subjects). The influence ofthe
disease on serum hormone concentrations can only be excluded by
prospective studies. Only three prospective studies have reported
oestradiol concentrations inpremenopausal womenandnonefound a
statistically significant association between serumoestradiol concen-
tration and risk of developing breast cancer (Wysowski et al, 1987;
Helzlsouer et al, 1994; Rosenberg et al, 1994).
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We report here the results of a prospective study designed to
investigate associations between endogenous hormone concentra-
tions and breast cancer risk in premenopausal women on the island
ofGuernsey. We tested the hypotheses that serum concentrations of
oestradiol, testosterone and luteal-phase progesterone are positively
associated with risk ofbreast cancer, whereas serum sex hormone-
binding globulin (SHBG) is negatively associated withrisk. Results
forurinary oestrogen excretion for 35 ofthese cases, which showed
that excretion was non-significantly lower in cases than in control
subjects, have recently been published (Key et al, 1996).
SUBJECTS AND METHODS
Study subjects and data collection
A total of6127 women aged 34 years and above who lived on the
island of Guernsey were recruited between 1977 and 1990.
Recruitment was in two phases, from 1977 to 1985 and from 1986
to 1990; 3680 women participated in both recruitment phases.
Participants completed a questionnaire at interview, height and
weight were measured and a blood sample was taken. Serum was
stored in 2-ml aliquots at-20°C.
Follow-up for the diagnosis of breast cancer was through
pathology reports (all dealt with by one pathology laboratory),
general practitioners, Guernsey death certificates and the Wessex
Cancer Registry. This registry covers Southampton where some
patients from Guernsey are referred for hospital treatment. Cases
were all women diagnosed with breast cancer subsequent to
recruitment up until the end of October 1994. A woman was
eligible for this analysis ifshe had notpreviously had cancer other
than non-melanoma skin cancer, if she was not using any exogen-
ous sex hormones at the time of blood donation, and if she
reported at interview that she was menstruating in her usual
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pattern and if her next menstrual period was within 42 days ofthe
interview date.
Control subjects were identified that matched a case on: age,
within 2 years; date of blood collection, within 1 year; and day of
menstrual cycle, within 1 day in the category of 1-29 days until
next menstrual period and within 2 days in the category of 30+
days. Three control subjects per case were randomly selected from
all those who were suitably matched. Serum was available for
64 cases and 191 control subjects, but was not available for four
additional eligible cases. The serum concentration of follicle-
stimulating hormone (FSH) was measured for all but three cases
and one control subject to evaluate an individual's true pre-
menopausal status. Two cases and five control subjects were found
to have a concentration of FSH greater than or equal to 35 IU 1-'
(the highest expected premenopausal concentration quoted by the
assay protocol) and were excludedfrom the analyses,together with
a further four matched control subjects ofthe excluded cases.
Hence, 62 cases and 182 control subjects are included in the
analyses. Serum progesterone and testosterone concentrations
were measured for all these women, oestradiol concentrations
were measured for all but one case, and SHBG concentrations
were available for all but nine cases and ten control subjects. Five
cases participated in both recruitment phases and donated two
blood samples; the blood samples donated at the first interview
have been used in these analyses.
Measurement of serum hormone concentrations
The samples were thawed on the day ofthe progesterone assay and
aliquots removed and refrozen for the oestradiol, testosterone and
FSH assays to be done at a later date. Samples for matched
case-control sets were analysed blind to case-control status in the
same assay batch. SHBG was measured in virtually all of the
blood samples from the Guernsey cohort as the study progressed.
Serum concentrations of oestradiol and progesterone were
measured using a radioimmunoassay kit (Diagnostic Products
Corporation, CA, USA). Testosterone concentrations were also
measured by radioimmunoassay kit (Immunodiagnostic Systems
Ltd., Tyne and Wear, UK). SHBG was measured by an in-house
liquid phase immunoradiometric assay (Hammond et al, 1985) in
the first recruitment phase (1977-1985) and by the same method
in kit form (Farmos Diagnostica, Oulansalo, Finland) in the
second recruitment phase (1986-1990). FSH concentrations were
measured by heterogeneous sandwich magnetic separation assay
(Bayer plc, Berkshire, UK).
The intra- and interassay coefficients ofvariation were 13.5% and
2.3% respectively at an oestradiol concentration of 371 pmol 1-1,
7.8% and 15.8% respectively at a progesterone concentration of
23 nmol 1-', 7.0% and 4.5% respectively at a testosterone concentra-
tion of 2.1 nmol 1- and 5.3% and 4.1% respectively at an SHBG
concentration of76.1 nmol 1-' (in-house protocol).All FSH measure-
ments were carried out in one assay; intra-assay variation was 1.2%
at a concentration of8.3 IU 1-1. The lowest detectable concentrations
were 30 pmol 1-1 oestradiol, 0.1 nmol 1-' progesterone, 0.35 nmol 1-l
testosterone, 0.1 nmol 1-l SHBG and 0.1 IU 1-' FSH.
Examination by linear regression of the relationship between
oestradiol, progesterone, testosterone and FSH concentrations and
duration ofblood sample storage showed that oestradiol concentra-
tions increased by 0.5% per year of storage (two-sided P = 0.97),
progesterone increased by 2.8% per year (two-sided P = 0.04),
testosterone increased by 3.2% per year (two-sided P <0.001) and
FSH concentrations increased by 3.3% per year (two-sided
P = 0.003). A similar relationship was noted previously for SHBG
(Moore etal, 1987),butthe duration ofstorage before SHBG assays
was relatively short. This phenomenon does not affect the
case-control comparisons because cases and control subjects were
matched foryearofblood collection.
Statistical analyses
Concentrations of oestradiol, progesterone, testosterone, SHBG
and FSH were logarithmically transformed to produce approxi-
mately normal distributions and the mean hormone concentrations
presented are geometric means. Associations between hormone
concentrations and other variables in the control subjects were
explored using Pearson partial correlation coefficients and
analysis of covariance. Geometric mean concentrations of the
hormones in the cases and control subjects were calculated and
compared using analysis ofcovariance.
Odds ratios for breast cancer in relation to concentrations of
oestradiol, progesterone (0-15 days before next menstrual cycle),
testosterone and SHBG were calculated for matched case-control
sets using conditional logistic regression and the significance of
lineartrends wasjudged by likelihood ratio tests. Odds ratios were
calculated using the natural log of the hormone concentrations
expressed as a continuous variable. Ninety-five per cent confi-
dence intervals and two-sided P-values are quoted. Statistical tests
were considered significant at P < 0.05. The EGRET statistical
package (Statistics and Epidemiology Research Corporation and
Cytel Software Corporation, Seattle, WA, USA) was used for
conditional logistic regression; all other analyses were performed
using SPSS (SPSS, Chicago, IL, USA).
Associations between oestradiol and progesterone concentrations
and other variables were adjusted for stage ofmenstrual cycle (0-2,
3-5, 6-8, 9-11, 12-15, 16-18, 19-21, 22-24 and 25+ days before
next menstrual period) and duration of blood storage. Associations
between testosterone and SHBG concentrations and other variables
were adjustedforstageofmenstrual cycle (0-2, 3-11, 12-15, 16-21
and 22+ days before next menstrual penod), and associations with
testosterone were furtheradjustedforduration ofblood storage. The
odds ratio analyses were adjusted separately for parity, first-degree
Table 1 Characteristics of breast cancer cases and control subjects
Cases Controls P-
(n = 62) (n = 182) value
Mean (s.e.) age at interview (years) 40.9 (0.6) 40.8 (0.3) 0.87
Mean (s.e.) age at menarche (years)a 13.1 (0.2) 13.0 (0.1) 0.55
Mean (s.e.) length of menstrual
cycle (days) 28.1 (0.6) 28.2 (0.4) 0.90
Mean (s.e.) weight (kg) 64.2 (1.3) 64.4 (0.8) 0.88
Mean (s.e.) height (cm) 163 (0.7) 161 (0.5) 0.18
Mean (s.e.) body mass index (kg m-2) 24.3 (0.4) 24.8 (0.3) 0.35
Percentage (s.e.) parous 87.1 (4.3) 91.8 (2.0) 0.40
Percentage (s.e.) reporting first-degree
family history 12.9 (4.3) 6.0 (1.8) 0.14
Percentage (s.e.) reporting past use of
oral contraceptives 77.4 (5.3) 65.4 (3.5) 0.11
Percentage (s.e.) reporting current
drug useb 24.6 (5.5) 29.8 (3.4) 0.53
a180 control subjects. bUse of prescribed or over-the-counter medication at
time of interview, 61 cases and 181 control subjects.
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Table 2 Correlation coefficients between sex hormone concentrations (natural log values) and other variables in control subjects
Oestradiol (n = 179) Progesterone (n = 92)a Testosterone (n = 182) SHBG (n = 156)
Correlation P. Correlation P. Correlation P. Correlation P.
coefficient value coefficient value coefficient value coefficient value
Progesterone 0.11 0.33
Testosterone 0.25 < 0.01 -0.04 0.69
SHBG <0.01 0.94 0.22 0.07 -0.26 <0.01
FSHb -0.32 < 0.01 -0.25 0.02 < 0.01 0.99 < 0.01 0.99
Age at interview -0.14 0.06 -0.15 0.17 0.06 0.49 -0.01 0.90
Body mass index -0.09 0.25 -0.20 0.06 0.23 < 0.01 -0.34 < 0.01
Values are geometric means. Concentrations of oestradiol and progesterone are adjusted for day of menstrual cycle in categories of 0-2, 3-5, 6-8, 9-11,
12-15, 16-18, 19-21, 22-24 and 25+ days before next menstrual period; concentrations of testosterone and SHBG are adjusted in categories of 0-2, 3-11,
12-15, 16-21 and 22+ days before next menstrual period. Concentrations of oestradiol, progesterone and testosterone are also adjusted for duration of blood
storage. aProgesterone concentrations are 0-15 days before next menstrual period. bCorrelations between FSH and sex hormone concentrations are based on
up to ten observations less than specified sample size.
Table 3 Sex hormone serum concentrations in cases and control subjects
Hormone (units) Days until next Cases Control subjects
menstrual period P.value
n Mean (95% Cl) n Mean (95% Cl)
Oestradiol (pmol 1-')
Early follicular 22+ 13 156 (112-217) 36 167 (137-204) 0.73
Late follicular 16-21 18 346 (272-439) 51 301 (261-347) 0.33
Mid-cycle 12-15 7 832 (540-1281) 24 475 (376-600) 0.04
Early luteal 3-11 12 394 (282-441) 35 398 (350-454) 0.94
Late luteal 0-2 11 256 (181-362) 33 223 (183-273) 0.51
Whole cycle Any 61 316 (276-362) 179 283 (262-307) 0.17
Progesterone (nmol 1-')
Early follicular 22+ 14 4.14 (2.98-5.77) 39 4.96 (4.07-6.04) 0.37
Late follicular 16-21 18 2.59 (1.99-3.36) 51 2.37 (2.03-2.77) 0.59
Mid-cycle 12-15 7 6.24 (3.14-12.4) 24 8.04 (5.55-11.6) 0.54
Early luteal 3-11 12 28.5 (20.7-39.2) 35 31.2 (25.8-37.6) 0.64
Late luteal 0-2 11 12.9 (8.28-20.2) 33 12.5 (9.64-16.1) 0.89
Testosterone (nmol 1-') Any 62 1.25 (1.12-1.40) 182 1.20 (1.13-1.28) 0.57
SHBG (nmol 1-') Any 53 69.4 (62.1-77.6) 156 64.2 (60.2-68.5) 0.24
Values are geometric means. Concentrations of oestradiol and progesterone are adjusted for day of menstrual cycle in categories of 0-2, 3-5, 6-8, 9-11,
12-15, 16-18, 19-21, 22-24 and 25+ days before next menstrual period; concentrations of testosterone and SHBG are adjusted in categories of 0-2, 3-11,
12-15, 16-21 and 22+ days before next menstrual period. Concentrations of oestradiol, progesterone and testosterone are also adjusted for duration of
blood storage.
family history ofbreastcancer, body mass index (BMI,kg m-2),past
use oforal contraceptives and the otherhormone concentrations.
RESULTS
Diagnosis ofbreast cancer was a mean of 8.0 years (range < 1-16
years) subsequent to blood collection. Breast cancer cases and
control subjects were almost identical in age at interview (a
matching criterion), age at menarche, length of menstrual cycle,
weight and BMI (kg m-2). Cases were on average 2 cm taller than
control subjects. A lower proportion of cases than control subjects
was parous, a higher proportion of cases reported a first-degree
family history ofbreast cancer and past use oforal contraceptives,
and a lowerproportion ofcases reported use ofprescribed or over-
the-counter medication at the time of interview. None of these
differences was statistically significant (Table 1).
Associations between hormones and other variables in
control subjects
Oestradiol concentration increased significantly with increasing and
testosterone concentration and decreased significantly with
increasing FSH concentration (Table 2). Progesterone concentration
measured 0-15 days before the next menstrual period decreased
significantly with increasing FSH concentration. Testosterone
concentration decreased significantly with increasing SHBG
concentration and increased significantly with increasing BMI.
SHBG concentration decreased significantly with increasing BMI.
The mean concentration oftestosterone was 12% lower (P = 0.06)
and the mean concentration of SHBG was 14% lower (P =0.04) in
women who had used oral contraceptives in the past. There were no
statistically significant associations between hormone concentrations
and parity (parous, nulliparous), first-degree family history ofbreast
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Table 4 Odds ratios for breast cancer in relation to serum hormone
concentrations
Hormone OR (95% Cl) P-value
Oestradiol 1.51 (0.87-2.63) 0.14
Progesteronea 0.76 (0-37-1.53) 0.44
Testosterone 1.22 (0.61-2.43) 0.57
SHBG 1.78 (0.77-4.12) 0.17
Odds ratios are estimated by conditional logistic regression for matched
case-control sets and are based on a 1 unit increase in the natural log of
hormone concentration. aProgesterone concentrations are 0-15 days before
next menstrual period.
cancer, age at menarche, length ofmenstrual cycle, number ofyears
since last use oforal contraceptives or use ofprescribed orover-the-
counter medication at the time ofinterview (results not shown).
Hormone concentrations in cases and control subjects
Table 3 shows that, in comparison with the control subjects, the
cases had a 12% higher mean oestradiol concentration (P =0.17),
4% higher testosterone concentration (P = 0.57) and 8% higher
SHBG concentration (P = 0.24) across the whole menstrual cycle.
The reported results were adjusted forduration ofblood storage and
day of menstrual cycle, although the unadjusted results were
similar, since these were matching criteria. Neither the exclusion of
29 breast cancer cases who were aged 50 years orolder atdiagnosis
and their matched control subjects nor the exclusion of ten cases
who donated blood less than 3 years before diagnosis and their
matched control subjects appreciably altered the difference in mean
oestradiol or testosterone concentrations between the cases and
control subjects. However, after excluding the ten cases who
donated blood less than 3 years before diagnosis and their matched
control subjects, the mean concentration ofSHBG was 16% higher
in the cases than in the control subjects (P = 0.04).
The concentrations of oestradiol and progesterone were
compared in the breast cancer cases and control subjects by five
stages of the menstrual cycle. The mean oestradiol concentration
was 75% higher in the cases than in the control subjects during the
mid-cycle phase (P = 0.04), and between 7% lower and 15%
higher in the cases at other stages of the cycle. The mean proges-
terone concentration was 9% lower in the cases during the early
luteal phase (P = 0.64) and 3% higher in the cases during the late
luteal phase (P = 0.89).
The odds ratios for breast cancer in relation to a unit increase in
the log ofthe hormone concentrations ofoestradiol, progesterone,
testosterone and SHBG are presented in Table 4. None of the
tests for linear trend was statistically significant. An odds ratio for
the difference between the median concentration in the control
subjects within the lowestthird ofthe hormone distribution andthe
median concentration in the control subjects within the highest
third ofthe distribution could be calculated for each hormone. The
odds ratios for breast cancer in women with relatively high serum
concentrations compared with women with lower concentrations
ofthe hormones were: follicular phase oestradiol (16+ days before
next menstrual period), OR = 1.71; luteal phase oestradiol (0-11
days before next menstrual period), OR = 1.67; progesterone
(0-15 days before next menstrual period), OR = 0.58; testosterone,
OR = 1.19; SHBG,OR = 1.58.
The odds ratios for oestradiol, progesterone and testosterone
were not substantially altered by any adjustments. After adjusting
SHBG concentration for past use of oral contraceptives, the odds
ratio rose to 2.45 (95% CI 1.01-5.89, P = 0.05).
DISCUSSION
These data are from a prospective study designed to investigate
associations between serum concentrations of sex hormones in
premenopausal women and risk of developing breast cancer. The
blood samples in this study were collected a mean of 8.0 years
before breast cancer diagnosis, and restriction of the analyses to
cases who donated blood 3 or more years before diagnosis
produced similar results to those quoted, so it is unlikely that the
small differences in serum hormone concentrations are caused by
the metabolic effects ofearly cancer. The results reliably represent
hormone measurements of premenopausal women, since women
with high serum concentrations ofFSH were excluded. The nega-
tive correlation of oestradiol and progesterone concentrations
with FSH concentration was observed at all ages and was not a
result of decreasing oestradiol and progesterone and increasing
FSH concentration as women approached the menopause.
Ourdata suggest that the mean oestradiol concentration overthe
complete menstrual cycle may be higher in women who develop
breast cancer than in control subjects, but the small difference was
not statistically significant. In the three other prospective studies
published, Wysowski et al (1987) reported a 16% lower mean
oestradiol concentration in breast cancer cases in samples taken
throughout the cycle, Helzlsouer et al (1994) reported a 17%
higher follicular phase oestradiol but a 29% lower luteal phase
oestradiol concentration in the cases, and Rosenberg et al (1994)
reported similar unadjusted mean oestradiol concentrations in the
cases and control subjects, although the mean concentration was
higher in the cases than the control subjects after adjusting for day
of cycle by spline regression. The most noticeable finding from
ourstudy is the 75% highermid-cycle serum oestradiol concentra-
tion in women who subsequently developed breast cancer
compared with the control subjects,butthis comparison was based
on only seven cases, was not an a priori hypothesis and could
simply be due to chance. Results for urinary oestrogen excretion
(Key et al, 1996) in 35 of the 62 cases differed somewhat from
those for serum oestradiol concentrations, but we believe serum
concentrations to be a more reliable indicator of levels of oestra-
diol in the breast tissue. Unfortunately, the two measurements
cannot be directly compared because the urine and blood samples
from each woman were not collected on the same day of the
menstrual cycle.
The concentration of SHBG is an important determinant of the
proportion of oestradiol that is non-protein bound, which is
thought to be the bioavailable fraction and has been hypothesized
to be inversely related to breast cancer risk (Siiteri et al, 1981).
Moore et al (1986) reported a 13% lower mean SHBG concentra-
tion in a subset of 12 premenopausal cases (which are also
included in this study) than in the control subjects. However,
Helzlsouer et al (1994) reported virtually identical concentrations
ofSHBG in cases and control subjects and we found a non-signif-
icantly higher mean SHBG concentration in the cases than in the
control subjects. After adjusting for past use of oral contracep-
tives, ourreported odds ratio forbreast cancer in relation to SHBG
concentration increased and was statistically significant. We report
a 14% lower concentration of SHBG in women who had used oral
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contraceptives in the past compared with those who had not,
whereas Key et al (1989) found only a 4% lower concentration
among 1243 premenopausal women within the Guernsey cohort
who had previously used oral contraceptives compared with 616
women who had not. So, although our results seem contrary to the
hypothesis for SHBG and breast cancer risk, it is still unclear how
past use of oral contraceptives, SHBG concentration and risk of
premenopausal breast cancer are truly associated.
Prospective epidemiological studies have provided only meagre
evidence for an association between raised luteal phase concentra-
tions ofprogesterone andbreast cancerrisk. Wysowski etal (1987)
found 29% lower levels of progesterone in cases than in control
subjects in samples taken throughout the cycle but did not report
data for luteal phase concentrations. Helzlsouer et al (1994)
reported a 94% higher median luteal phase concentration ofprog-
esterone in women who developed breast cancer than in control
subjects, based on only nine cases. We found almost identical
serum concentrations of progesterone in the cases and the control
subjects during the luteal phase ofthe cycle.
Several case-control studies have reported an association
between raised concentrations of testosterone and premenopausal
breast cancer risk, but the only two prospective studies that have
reported measurement of serum testosterone concentrations have
not supported this hypothesis. Wysowski et al (1987) found no
difference in mean testosterone concentrations and we report a
non-significant 4% higher mean concentration of testosterone in
the breast cancer cases than in the control subjects.
Our data include a relatively large number of premenopausal
breast cancer cases in a prospective study of endogenous sex
hormones and breast cancer. We found the mean oestradiol
concentration to be 12% higher in the cases than in the control
subjects. Although this small difference was not statistically
significant, it could, nevertheless, be aetiologically important. It is
clear that larger prospective studies are needed to clarify these
results, perhaps using multiple blood samples collected at different
phases ofthe menstrual cycle.
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